Erythropoiesis-stimulating agent withdrawal and oxidative stress in hemodialysis

Clinical Nephrology

Volumn 71, Issue 5, 2009, Pages 521-526

  Monostori, Peter ^a   Hraczko Z ^a   Karg, E ^a   Varga, I S ^a   Kiss, Z ^b   Boros, T ^a   Kiss, E ^a   Haszon, I ^a   Papp, F ^a   Sumegi V ^a   Bereczki, C ^a   Turi S ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b Amgen Ltd   (Hungary)

Author keywords

Antioxidant enzyme activity; Erythropoietin; ESA; Glutathione; Lipid peroxidation; Therapy withdrawal

Indexed keywords

ANTIANEMIC AGENT; CATALASE; GLUTATHIONE; GLUTATHIONE DISULFIDE; MALONALDEHYDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; SUPEROXIDE DISMUTASE; DRUG DERIVATIVE; ERYTHROPOIETIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CHRONIC GLOMERULONEPHRITIS; CHRONIC PYELONEPHRITIS; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY HYPOPLASIA; MALE; OXIDATIVE STRESS; ANEMIA; BLOOD; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; ENZYMOLOGY; FOLLOW UP; METABOLISM; METHODOLOGY; MIDDLE AGED; PHYSIOLOGY; PROGNOSIS; RENAL REPLACEMENT THERAPY; TREATMENT WITHDRAWAL;

ANEMIA; ERYTHROCYTES; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FOLLOW-UP STUDIES; GLUTATHIONE DISULFIDE; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROGNOSIS; RENAL DIALYSIS; SUPEROXIDE DISMUTASE; WITHHOLDING TREATMENT;

EID: 67649400673     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP71521     Document Type: Article

References (30)

1. Alfrey CP, Fishbane S. Implications of neocytolysis for optimal management of anaemia in chronic kidney disease. Nephron Clin Pract. 2007; 106: c149-c156.
2. Alhamdani MS. Impairment of glutathione biosynthetic pathway in uraemia and dialysis. Nephrol Dial Transplant. 2005; 20: 124-128.
3. Annuk M, Zilmer M, Lind L, Linde T, Fellstrom B. Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol. 2001; 12: 2747-2752.
4. Boaz M, Matas Z, Biro A, Katzir Z, Green M, Fainaru M, Smetana S. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int. 1999; 56: 1078-1083.
5. Borawski J, Mysliwiec M. Effects of recombinant erythropoietin therapy on circulating endothelial markers in hemodialysis patients. Clin Appl Thromb Hemost. 2002; 8: 77-84.
6. Calò LA, Stanic L, Davis PA, Pagnin E, Munaretto G, Fusaro M, Landini S, Semplicini A, Piccoli A. Effect of epoietin on HO-1 mRNA level and plasma antioxidants in hemodialysis patients. Int J Clin Pharmacol Ther. 2003; 41: 187-192.
7. Clark MR. Senescence of red blood cells: progress and problems. Physiol Rev. 1988; 68: 503-554.
8. Coxon A, Sinclair A, Archibeque I, Estrada J, Kaufman S, Rogers N, Swift S, Tran L, Elliott S. Endothelial cells express no detectable erythropoietin receptor protein and erythropoietin does not induce angiogenesis in vivo (abstract). Blood. 2007; 110: 4077.
9. Deicher R, Hörl WH. Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease. Drugs. 2004; 64: 499-509.
10. Dickinson DA, Moellering DR, Iles KE, Patel RP, Levonen AL, Wigley A, Darley-Usmar VM, Forman HJ. Cytoprotection against oxidative stress and the regulation of glutathione synthesis. Biol Chem. 2003; 384: 527-537.
11. Essers MA, Weijzen S, de Vries-Smits AM, Saarloos I, de Ruiter ND, Bos JL, Burgering BM. FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. EMBO J. 2004; 23: 4802-4812.
12. Hattangadi SM, Lodish HF. Regulation of erythrocyte lifespan: do reactive oxygen species set the clock? J Clin Invest. 2007; 117: 2075-2077.
13. Jacobs-Helber SM, Ryan JJ, Sawyer ST. JNK and p38 are activated by erythropoietin (EPO) but are not induced in apoptosis following EPO withdrawal in EPO-dependent HCD57 cells. Blood. 2000; 96: 933-940.
14. Katavetin P, Tungsanga K, Eiam-Ong S, Nangaku M. Antioxidative effects of erythropoietin. Kidney Int Suppl. 2007; 107: S10-15.
15. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffer PJ, Huang TT, Bos JL, Medema RH, Burgering BM. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature. 2002; 419: 316-321.
16. Kumar S, Bandyopadhyay U. Free heme toxicity and its detoxification systems in human. Toxicol Lett. 2005; 157: 175-188.
17. Lahera V, Goicoechea M, de Vinuesa SG, Oubiña P, Cachofeiro V, Gómez-Campderá F, Amann R, Luño J. Oxidative stress in uremia: the role of anemia correction. J Am Soc Nephrol. 2006; 17: S174-177.
18. Lim PS, Wei YH, Yu YL, Kho B. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol DialTransplant. 1999; 14: 2680-2687.
19. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant. 2003; 18: 1272-1280.
20. Macdougall IC. Anaemia of chronic kidney disease. Medicine. 2007; 35: 457-460.
21. Mimic-Oka J, Simic T, Djukanovic L. Epoietin treatment improves red blood cell and plasma antioxidant capacity in hemodialysis patients. Ren Fail. 2002; 24: 77-87.
22. Nemeth I, Boda D. Blood glutathione redox ratio as a parameter of oxidative stress in premature infants with IRDS. Free Radic Biol Med. 1994; 16: 347-353.
23. Peuchant E, Carbonneau MA, Dubourg L, Thomas MJ, Perromat A, Vallo C, Clerc M. Lipoperoxidation in plasma and red blood cells of patients undergoing haemodialysis: vitamins A, E, and iron status. Free Radic Biol Med. 1994; 16: 339-346.
24. Rice L, Alfrey CP, Driscoll T, Whitley CE, Hachey DL, Suki W. Neocytolysis contributes to the anemia of renal disease. Am J Kidney Dis. 1999; 33: 59-62.
25. Siems W, Quast S, Carluccio F, Wiswedel I, Hirsch D, Augustin W, Hampi H, Riehle M, Sommerburg O. Oxidative stress in chronic renal failure as a cardiovascular risk factor. Clin Nephrol. 2002; 58 Suppl 1: S12-19.
26. Tattersall J, Martin-Malo A, Pedrini L, Basci A, Canaud B, Fouque D, Haage P, Konner K, Kooman J, Pizzarelli F, Tordoir J, Vennegoor M, Wanner C, ter Wee P, Vanholder R. EBPG guideline on dialysis strategies. Nephrol Dial Transplant. 2007; 22: ii5-21.
27. Turi S, Nemeth I,Varga I, Bodrogi T, Matkovics B. The effect of erythropoietin on the cellular defence mechanism of red blood cells in children with chronic renal failure. Pediatr Nephrol. 1992; 6: 536-541.
28. Turi S, Nemeth I, Varga I, Matkovics B, Dobos E. Erythrocyte defense mechanisms against free oxygen radicals in haemodialysed uraemic children. Pediatr Nephrol. 1991; 5: 179-183.
29. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007; 39: 44-84.
30. Zwolinska D, Grzeszczak W, Szczepanska M, Kilis-Pstrusinska K, Szprynger K. Lipid peroxidation and antioxidant enzymes in children on maintenance dialysis. Pediatr Nephrol. 2006; 21: 705-710.